**Abstract**

**Background:** Long-term treatment with antipsychotic drugs in patients with schizophrenia occasionally causes dopamine supersensitivity psychosis (DSP), which is characterized by acute exacerbation of psychiatric symptoms due to discontinuation of antipsychotics, tolerance to the therapeutic effects of antipsychotics, and presence of tardive dyskinesia. Many studies have shown that DSP is attributed to compensatory upregulation of dopamine D~2~ receptor (D~2~R) density as a result of chronic and excessive blockade of D~2~Rs by antipsychotics (Iyo et al., 2013).

**Objective:** Blonanserin (BNS) is an atypical antipsychotic drug, which has high affinity for D~2~R, dopamine D~3~ receptor (D~3~R), and 5-HT~2A~ receptor and weak or very low affinity for other receptors. The present study investigated whether chronic treatment with BNS causes DSP.

**Method:** Male Wistar rats (6-week-old) were orally administered haloperidol (HPD) and BNS, at doses of 1.1 mg/kg and 0.78 mg/kg, respectively, or vehicle twice daily for 28 days. These doses were equivalent to two times the 50% effective doses of HPD and BNS in a methamphetamine-induced hyperlocomotion test in rats, respectively. Seven days after drug discontinuation, a quinpirole (0.5 mg/kg, sc)-induced hyperlocomotion test or a radioligand binding assay using ^3^H-raclopride for striatal D~2~R was conducted. We also investigated the effects of chronic treatments with HPD and BNS on D~2~R and D~3~R mRNA levels in five brain regions.

**Results:** Chronic treatment with HPD significantly increased locomotor activity and D~2~R density (i.e. Bmax) compared with vehicle treatment. In contrast, chronic BNS treatment did not affect both locomotor activity and D~2~R density. There were no changes in D~2~R and D~3~R mRNA levels in chronic HPD- and BNS-treated groups, respectively.

**Conclusion:** The present results suggest that long-term treatment with BNS is less likely to cause DSP compared to treatment with the typical antipsychotic drug, HPD.
